RESUMO
Pleomorphic adenoma (PA) is by far the most common salivary gland tumor. It is well known that PA can undergo malignant transformation. However, in rare occasions it can metastasize preserving its benign phenotype. Metastasizing pleomorphic adenoma (MPA) constitutes an extremely rare tumor. Here we are reporting an unusual MPA affecting the mandible that was preceded by a submandibular gland pleomorphic adenoma.
Assuntos
Adenoma Pleomorfo/patologia , Recidiva Local de Neoplasia/patologia , Neoplasias das Glândulas Salivares/patologia , Adolescente , Feminino , Humanos , Mandíbula/patologiaRESUMO
Bisphosphonates are commonly prescribed for the treatment of osteoporosis and bone cancers. These drugs come in both intravenous and oral forms. Because these drugs have become more prevalent, there have been increased reports of bisphosphonate-related osteonecrosis of the jaws (BRONJ). This case presentation focuses on a 50-year-old woman with a 10-year history of monthly Zometa (zoledronic acid) use for treatment of multiple myeloma, resulting in BRONJ with a very unfavorable outcome. Its purpose is to depict how the chronic use of intravenous (i.v.) bisphosphonates can lead to bisphosphonate-related osteonecrosis of the jaw (BRONJ), and to present treatment options, including conservative measures, the dentist may be able to employ in the early phases of the disease, along with the indications for jaw resection. Osteonecrosis of the jaws in association with bisphosphonate therapy is a very serious condition with which all dentists should be familiar. When the osteonecrosis begins, it can be very painful to the patient, difficult to treat, and can lead to very deleterious sequelae.
Assuntos
Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/diagnóstico , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/cirurgia , Conservadores da Densidade Óssea/efeitos adversos , Difosfonatos/efeitos adversos , Imidazóis/efeitos adversos , Comorbidade , Feminino , Humanos , Pessoa de Meia-Idade , Mieloma Múltiplo/tratamento farmacológico , Ácido ZoledrônicoRESUMO
The control of hemorrhage is a key component for the clinician to understand before performing oral surgical procedures. Hemostasis may be obtained primarily by local hemostatic measures. If hemostasis is not achieved with this modality, various hemostatic agents exist, which may be used as adjuncts to obtain hemostasis. Preoperative, perioperative, and postoperative methodologies toward hemostasis in oral surgery have been presented.
Assuntos
Hemostasia Cirúrgica/métodos , Procedimentos Cirúrgicos Bucais/métodos , Anticoagulantes/uso terapêutico , Perda Sanguínea Cirúrgica/prevenção & controle , Interações Medicamentosas , Técnicas Hemostáticas , Hemostáticos/uso terapêutico , Humanos , Cuidados Intraoperatórios , Planejamento de Assistência ao Paciente , Educação de Pacientes como Assunto , Inibidores da Agregação Plaquetária/uso terapêutico , Hemorragia Pós-Operatória/prevenção & controle , Fatores de Risco , Vasoconstritores/uso terapêuticoRESUMO
Hemostasis is an integral and very important aspect of surgical practice. As a rule, most bleeding from dental surgery can be controlled by pressure. When the application of pressure does not yield satisfactory results, or where more effective hemostasis is required, hemostatic agents are used. These agents act to stop bleeding either mechanically or by augmenting the coagulation cascade. Some of the newer agents that are available to the dental profession have been presented.